<DOC>
	<DOCNO>NCT00836875</DOCNO>
	<brief_summary>The purpose study evaluate safety profile voriconazole ( antifungal drug ) use child invasive aspergillosis ( IA ) rare systemic fungal infection .</brief_summary>
	<brief_title>A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis ( Fungal Infection ) And Other Rare Molds In Children</brief_title>
	<detailed_description />
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Immunocompromised clinically compatible illness . Diagnosis proven probable possible Invasive Aspergillosis ( base modify version revise EORTC/MSG consensus definition ) . Diagnosis infection due Scedosporium Fusarium specie . Male female 2 17 year age . Females childbearing potential must negative pregnancy test use appropriate contraception . Allergy hypersensitivity azole drug . Female subject pregnant lactating . Patients receive four day antifungal drug treat current episode invasive aspergillosis rare mold infection . Received within 24 hour prior enrollment drug may cause QT interval prolongation . Significant liver , kidney heart dysfunction . Not expect survive least 5 day .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pediatrics voriconazole invasive fungal infection invasive aspergillosis immunocompromized</keyword>
</DOC>